Unexpected protein structure findings could lead to new therapies
Scientists have determined unexpected characteristics of a key protein linked to blood pressure control and to nerve growth, pain control and heart tissue regeneration. The findings, published April 5 online in the journal Nature, open doors to potential new therapies to control cardiovascular disease and pain.
The protein, called AT2, is one of a group of receptors that interact with the angiotensin II hormone, which regulates blood pressure. Angiotensin II receptor proteins are important factors in diabetes, hypertension, heart attack and congestive heart failure, and stroke.
AT2 is also a member of a superfamily of proteins called G protein-coupled receptors, or GPCRs. These receptor proteins span the cell membrane, responding to different stimuli outside the cell— nutrients, hormones and even light — then triggering responses inside the cell.
Because they are active in so many physiological processes in both healthy and disease states, GPCRs like AT2 are important drug targets.
Delving into the mystery
While researchers have long been aware of AT2’s physiological effects, how it acts remains a mystery.
“AT2’s activity has been observed on the organ and organism level, but how it works on the molecular level is not understood,” said Vadim Cherezov, professor of chemistry, biological sciences, and physics and astronomy at USC Dornsife.
That’s in part because AT2 doesn’t behave like other GPCRs, according to Cherezov and Vsevolod Katritch, assistant professor of biological sciences and chemistry at USC Dornsife. Both scientists are also members of the Bridge Institute at the USC Michelson Center for Convergent Bioscience.
A depiction of the AT2 receptor (gray spirals and filaments), including helix VIII (red). Image by Greg Stewart/SLAC National Accelerator Laboratory.
“AT2 does not work through canonical signaling pathways for GPCRs,” Katritch said. “It doesn’t activate a G protein and it doesn’t work through arrestins.”
In most cases, G proteins and a group of proteins called arrestins interact with a cleft that opens up on the intracellular side of GPCRs upon activation. When a stimulus triggers the GPCR from outside the cell, the GPCR activates a G protein or arrestin within the cell, which then relays the signal to other proteins in the cell, and so on, in something akin to a game of molecular “telephone.”
AT2, however, works through some other, currently unknown mechanisms of relaying the signals into the cell.
To better understand AT2, Cherezov, Katritch and other scientists at the Bridge Institute collaborated with researchers at the Stanford Linear Accelerator Center (SLAC), Arizona State University and Merck & Co. to clarify its structure.
The team bound two different molecules to AT2 as part of the process. The first molecule adhered only to AT2. The second bound both AT2 and its close relative, AT1.
The scientists then used X-ray crystallography at a very powerful X-ray free-electron laser (XFEL) source to determine AT2’s structure. The SLAC facility, which hosts the world’s first hard XFEL known as the Linac Coherent Light Source (LCLS), was key to uncovering these new findings.
“This kind of room-temperature measurement on interesting membrane protein targets is something that LCLS is well-suited to perform,” said Mark Hunter, staff scientist at SLAC. “Membrane proteins remain elusive targets for high-resolution structural studies, and researchers can spend many years trying to obtain crystals that are well ordered and large enough to use at conventional light sources.”
The X-ray crystallography results produced a trio of surprises.
First, even though the two binding molecules were designed to inhibit and neutralize AT2, the researchers found that both seemed to do the opposite.
The Coherent X-ray Imaging experimental station at SLAC’s Linac Coherent Light Source. Photo by Brad Plummer/SLAC National Accelerator Laboratory.
“These molecules were derived from AT1 receptor blockers, therefore it was unexpected to find that they transform the AT2 receptor in an active-like state,” Cherezov said.
The scientists also saw that a helical section of the AT2 protein blocked the site where G proteins and arrestins normally interact.
In most GPCRs, this flap of protein, known as helix VIII, lies along the inner surface of the cell membrane. “But in AT2, it’s down, physically blocking the G protein and arrestin binding site,” Cherezov said. “That may explain why nobody could detect signaling through G proteins or arrestins when studying AT2.”
Finally, the crystal structure revealed previously unknown differences between the sites where small molecules, such as drugs, bind to AT2 and AT1.
“The idea was always that receptors that are closely related and are activated by the same signal peptide should have similar binding pockets, so most drug discovery efforts for AT2 focused on the same chemical scaffolding that previously worked for AT1,” Katritch said. “The startling differences between AT2 and AT1 ligand pockets that we see now will help us to have a fresh start on designing smaller, more drug-like molecules that are tailored to fit the AT2 receptor, which could set the drug discovery process in a different direction.”
First step to targeted therapies
While noting that further research is needed, Cherezov said the current discovery is an important first step both to better understanding of similar atypical GPCRs and to potential new therapies.
“The structure gives us the first clue of what’s happening on a molecular level,” he said. “We need to study further to really understand what other proteins it interacts with and how AT2 propagates signals in the cell.
Vadim Cherezov, professor of chemistry, biological sciences, and physics and astronomy.
“This information then could be used to design selective drugs that specifically target AT2 and not AT1 or other GPCRs,” he explained. That may be good news for patients coping with chronic conditions such as cardiovascular disease, diabetes and pain.
This study was done as a part of the GPCR Consortium, a nonprofit collaboration between academic and biopharmaceutical industry organizations. The consortium, which includes USC, two universities in China and nine pharmaceutical companies, aims to advance GPCR research for drug development.
Other USC Dornsife researchers on the study include first author Haitao Zhang; Gye Won Han; Alexander Batyuk; Andrii Ishchenko; Kate L. White; Nilkanth Patel; Anastasiia Sadybekov; and Raymond Stevens, Provost Professor of Biological Sciences, Chemistry, Neurology, Physiology and Biophysics, and Chemical Engineering and Materials Science, and director of the Bridge Institute.
Researchers from Zhejiang University in China and the Center for Free Electron Laser Science at the DESY lab in Germany also contributed to the study.
The work was supported by the National Institutes of Health grants R01 GM108635 and U54 GM094618; National Science Foundation grant 1231306; and the Helmholtz Association.